A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Epcoritamab
DRUG: Lenalidomide
DRUG: Ibrutinib
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride [HCl]
DRUG: Prednisone
DRUG: Polatuzumab Vedotin
DRUG: CC-99282

Sponsor

Genmab

Collaborators

AbbVie